Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics announced the grant of inducement stock options covering 139,930 shares to seventeen new non-executive employees on July 16, 2026, with an exercise price of $4.66 per share and a three-year vesting schedule. The grants were made under the company's Amended and Restated 2021 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).